Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ad-Free, Unlimited access)​
NO CREDIT CARD REQUIRED
NPCE logo NPCE
Upturn stock ratingUpturn stock rating
NPCE logo

Neuropace Inc (NPCE)

Upturn stock ratingUpturn stock rating
$9.11
Last Close (24-hour delay)
upturn advisory
PASS
  • BUY Advisory
  • SELL Advisory (Profit)​
  • SELL Advisory (Loss)​
  • Profit
  • Loss
  • Pass (Skip investing)
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK

Upturn Advisory Summary

08/28/2025: NPCE (3-star) is currently NOT-A-BUY. Pass it for now.

Upturn Star Rating

rating

Moderate Performance

These Stocks/ETFs, based on Upturn Advisory, typically align with the market average, offering steady but unremarkable returns.

Number of Analysts

rating

8 Analysts rated it

Limited analyst coverage, niche firm, research info may be scarce.

1 Year Target Price $16.75

1 Year Target Price $16.75

Analysts Price Target For last 52 week
$16.75 Target price
52w Low $5.45
Current$9.11
52w High $18.98

Analysis of Past Performance

Type Stock
Historic Profit 181.14%
Avg. Invested days 38
Today’s Advisory PASS
Upturn Star Rating Upturn stock ratingUpturn stock rating
Upturn Advisory Performance Upturn Advisory Performance 3.0
Stock Returns Performance Upturn Returns Performance 5.0
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 08/28/2025

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 301.37M USD
Price to earnings Ratio -
1Y Target Price 16.75
Price to earnings Ratio -
1Y Target Price 16.75
Volume (30-day avg) 8
Beta 1.9
52 Weeks Range 5.45 - 18.98
Updated Date 08/29/2025
52 Weeks Range 5.45 - 18.98
Updated Date 08/29/2025
Dividends yield (FY) -
Basic EPS (TTM) -0.82

Analyzing Revenue: Products, Geography and Growth

Revenue by Geography

Geography revenue - Year on Year

Earnings Date

Report Date 2025-08-12
When -
Estimate -0.22
Actual -0.26

Profitability

Profit Margin -29.29%
Operating Margin (TTM) -29.01%

Management Effectiveness

Return on Assets (TTM) -12.39%
Return on Equity (TTM) -176.94%

Valuation

Trailing PE -
Forward PE -
Enterprise Value 310750446
Price to Sales(TTM) 3.4
Enterprise Value 310750446
Price to Sales(TTM) 3.4
Enterprise Value to Revenue 3.51
Enterprise Value to EBITDA -16.94
Shares Outstanding 33081500
Shares Floating 22523207
Shares Outstanding 33081500
Shares Floating 22523207
Percent Insiders 2.71
Percent Institutions 82.15

ai summary icon Upturn AI SWOT

Neuropace Inc

stock logo

Company Overview

overview logo History and Background

NeuroPace, Inc. was founded in 1997 and is a commercial-stage medical device company focused on developing and commercializing innovative therapies to treat neurological disorders, primarily epilepsy. The company's initial focus was on developing the RNS System.

business area logo Core Business Areas

  • Neuromodulation: Developing and commercializing the RNS System for responsive neuromodulation to treat epilepsy. This is their core business.

leadership logo Leadership and Structure

The leadership team includes Michael Favet, CEO, and various VPs overseeing different departments. NeuroPace has a typical corporate structure with a board of directors and executive management.

Top Products and Market Share

overview logo Key Offerings

  • RNS System: The RNS System is the company's primary product. It is a closed-loop responsive neurostimulation system designed to prevent seizures by delivering targeted electrical stimulation to the seizure focus in the brain. Competitors would be other epilepsy treatments like medication, surgery, or alternative neuromodulation devices (e.g., vagus nerve stimulation, deep brain stimulation).

Market Dynamics

industry overview logo Industry Overview

The neuromodulation market is growing, driven by increasing prevalence of neurological disorders and advancements in technology. Epilepsy treatment represents a significant segment of this market.

Positioning

NeuroPace is positioned as a leader in responsive neuromodulation for epilepsy. The RNS System is the only FDA-approved closed-loop neurostimulation system for epilepsy.

Total Addressable Market (TAM)

The total addressable market for epilepsy treatments is estimated to be billions of dollars. NeuroPace is targeting a subset of this market, specifically patients with drug-resistant epilepsy who are not suitable for other surgical interventions. The TAM for RNS system could be in the hundreds of millions to low billions.

Upturn SWOT Analysis

Strengths

  • FDA-approved technology
  • First-mover advantage in responsive neurostimulation
  • Demonstrated efficacy in clinical trials
  • Proprietary technology

Weaknesses

  • High cost of the RNS System
  • Complex implantation procedure
  • Limited market penetration to date
  • Dependence on a single product

Opportunities

  • Expanding indications for the RNS System
  • Increasing awareness and adoption of responsive neuromodulation
  • Developing next-generation neuromodulation technologies
  • Partnerships with hospitals and epilepsy centers

Threats

  • Competition from other epilepsy treatments
  • Reimbursement challenges
  • Technological advancements by competitors
  • Regulatory changes

Competitors and Market Share

competitor logo Key Competitors

  • MRK
  • ABT
  • BSX

Competitive Landscape

NeuroPace has an advantage with its closed-loop system but faces competition from established players like Medtronic (MRK) and Abbott (ABT) in the broader neuromodulation market.

Growth Trajectory and Initiatives

Historical Growth: NeuroPace's growth has been dependent on RNS System adoption and revenue generation.

Future Projections: Analyst projections estimate continued revenue growth driven by increased adoption of the RNS System.

Recent Initiatives: Recent initiatives likely include expanding sales and marketing efforts, conducting clinical trials for new indications, and developing next-generation technologies.

Summary

NeuroPace is a promising medical device company with a unique technology for treating epilepsy. The company's strength lies in its FDA-approved RNS System and first-mover advantage. However, the high cost and complex implantation pose challenges. Expanding indications and partnerships could drive future growth.

Peer Comparison

Sources and Disclaimers

Data Sources:

  • NeuroPace Investor Relations
  • SEC Filings (10K, 10Q)
  • Analyst Reports
  • Company Press Releases

Disclaimers:

This analysis is based on publicly available information and is not financial advice. Market share estimates are approximate. Financial data needs to be updated with the latest quarterly filings.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.

About Neuropace Inc

Exchange NASDAQ
Headquaters Mountain View, CA, United States
IPO Launch date 2021-04-22
CEO, President & Director Mr. Joel D. Becker
Sector Healthcare
Industry Medical Devices
Full time employees 209
Full time employees 209

NeuroPace, Inc. operates as a medical device company in the United States. The company develops RNS system, a brain-responsive neuromodulation system that delivers personalized, real-time treatment at the seizure source for treating drug-resistant focal epilepsy. Its RNS System includes RNS neurostimulator, cortical strip and depth leads, and Patient Remote Monitor, as well as other implantable and non-implantable accessories. In addition, the company provides physician tablet and patient data management system; and nSight Platform, which facilitates ongoing patient monitoring and streamlines patient support. It sells its products to hospital facilities for initial RNS System implant procedures and for replacement procedures. NeuroPace, Inc. was incorporated in 1997 and is headquartered in Mountain View, California.